) recently announced the results of a study which demonstrated
that the company's non-invasive Pleth Variability Index (PVI)
parameter helps clinicians optimize fluid administration for
abdominal surgical patients under combined general and epidural
The results of the study were published in the Journal of
Monitoring and Computing as well. Following the announcement,
shares of MASI rose 0.9% in the subsequent trading sessions to
close at $26.92 yesterday.
GEN-EPI reduces the risk of respiratory complications and
duration of stay in hospitals but requires proper fluid
management. Multiple dynamic parameters are available to help
clinicians predict fluid responsiveness and improve fluid
management. However, most of these parameters require invasive
and/or complex methods.
In contrast, MASI's PVI parameter is non-invasive and can be
obtained with any Masimo SET or rainbow sensor. PVI helps
clinicians to continuously assess the fluid status of patients in
order to examine whether patients will benefit from fluid
administration, thus enabling personalized and goal-directed
The study was conducted at Shanghai First People's Hospital in
Shanghai, China, to assess the impact of PVI as a goal-directed
fluid parameter. It enrolled 30 patients who underwent elective
abdominal surgery under GEN-EPI.
Investigators used a Masimo Radical-7 rainbow SET Pulse
CO-Oximeter, which automatically calculated and displayed PVI.
The total average amount of fluid infused in PVI-guided fluid
therapy group was significantly lower than the amount of fluid in
the control group.
Recent research has shown that higher blood lactate levels in the
perioperative period are related with postoperative complications
and the average hospitalization time. The study concluded that
PVI-based goal-directed fluid management in major abdominal
surgery patients under GEN-EPI helps in optimizing fluid
management by reducing unnecessary fluid administration and blood
lactate levels during surgery. It enables clinicians to
understand the fluid level of their patients, thus improving
MASI reported a 19.2% rise in earnings to 31 cents per share for
the fourth quarter of 2013 which were in line with the Zacks
Consensus Estimate. Revenues in the quarter (including royalties)
increased 7.8% to $142.4 million, missing the Zacks Consensus
Estimate of $145.0 million.
Currently, MASI carries a Zacks Rank #3 (Hold). Better-ranked
stocks worth a look in the medical instruments industry are
Syneron Medical Ltd.
Delcath Systems, Inc.
). All the three stocks sport a Zacks Rank #1 (Strong Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis
DELCATH SYS INC (DCTH): Free Stock Analysis
SYNERON MED LTD (ELOS): Free Stock Analysis
MASIMO CORP (MASI): Free Stock Analysis
To read this article on Zacks.com click here.